Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Crystal Watson

Showing results (21-30 of 65) with videos related to

Pageof 7
Sort By:
The Journal of Dermatological Treatment|June 7, 2012
Psoriasis treatment patterns with etanercept and adalimumab in a United States health plan populationBenjamin Chastek, Kathleen M Fox, Crystal Watson, et al.
Journal of Medical Economics|January 24, 2022
Mean lifetime survival estimates following solid organ transplantation in the US and UKChristopher N Graham, Crystal Watson, Arie Barlev, et al.
Journal of Medical Economics|May 13, 2010
Etanercept treatment patterns in managed-care patients with psoriasis or psoriatic arthritisSarah Thayer, Crystal Watson, Rui Song, et al.
Advances in Therapy|August 14, 2012
Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settingsMachaon Bonafede, Kathleen M Fox, Crystal Watson, et al.
Current Medical Research and Opinion|December 3, 2013
A benefit-risk analysis of natalizumab in the treatment of patients with multiple sclerosis when considering the risk of progressive multifocal leukoencephalopathyAnna Walker, Crystal Watson, Stamatia T Alexopoulos, et al.
The Journal of Dermatological Treatment|February 28, 2013
Treatment patterns with etanercept and adalimumab for psoriatic diseases in a real-world settingMachaon Bonafede, Barbara H Johnson, Kathleen M Fox, et al.
Neurology and Therapy|September 8, 2023
Treatment Patterns and Unmet Need for Patients with Progressive Multiple Sclerosis in the United States: Survey Results from 2016 to 2021Crystal Watson, Dhanalakshmi Thirumalai, Arie Barlev, et al.
Advances in Therapy|March 14, 2012
Cost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysisMachaon M K Bonafede, Shravanthi R Gandra, Crystal Watson, et al.
Current Medical Research and Opinion|March 16, 2013
Dosing patterns of three tumor necrosis factor blockers among patients with rheumatoid arthritis in a large United States managed care populationMaxine D Fisher, Crystal Watson, Kathleen M Fox, et al.
Clinicoeconomics and Outcomes Research : CEOR|February 17, 2017
Health care resource utilization before and after natalizumab initiation among patients with multiple sclerosis in GermanyCrystal Watson, Christine Prosser, Sebastian Braun, et al.
Pageof 7

Showing results (21-30 of 65) with videos related to

Sort By:
Pageof 7
The Journal of Dermatological Treatment|June 7, 2012
Psoriasis treatment patterns with etanercept and adalimumab in a United States health plan populationBenjamin Chastek, Kathleen M Fox, Crystal Watson, et al.
Journal of Medical Economics|January 24, 2022
Mean lifetime survival estimates following solid organ transplantation in the US and UKChristopher N Graham, Crystal Watson, Arie Barlev, et al.
Journal of Medical Economics|May 13, 2010
Etanercept treatment patterns in managed-care patients with psoriasis or psoriatic arthritisSarah Thayer, Crystal Watson, Rui Song, et al.
Advances in Therapy|August 14, 2012
Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settingsMachaon Bonafede, Kathleen M Fox, Crystal Watson, et al.
Current Medical Research and Opinion|December 3, 2013
A benefit-risk analysis of natalizumab in the treatment of patients with multiple sclerosis when considering the risk of progressive multifocal leukoencephalopathyAnna Walker, Crystal Watson, Stamatia T Alexopoulos, et al.
The Journal of Dermatological Treatment|February 28, 2013
Treatment patterns with etanercept and adalimumab for psoriatic diseases in a real-world settingMachaon Bonafede, Barbara H Johnson, Kathleen M Fox, et al.
Neurology and Therapy|September 8, 2023
Treatment Patterns and Unmet Need for Patients with Progressive Multiple Sclerosis in the United States: Survey Results from 2016 to 2021Crystal Watson, Dhanalakshmi Thirumalai, Arie Barlev, et al.
Advances in Therapy|March 14, 2012
Cost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysisMachaon M K Bonafede, Shravanthi R Gandra, Crystal Watson, et al.
Current Medical Research and Opinion|March 16, 2013
Dosing patterns of three tumor necrosis factor blockers among patients with rheumatoid arthritis in a large United States managed care populationMaxine D Fisher, Crystal Watson, Kathleen M Fox, et al.
Clinicoeconomics and Outcomes Research : CEOR|February 17, 2017
Health care resource utilization before and after natalizumab initiation among patients with multiple sclerosis in GermanyCrystal Watson, Christine Prosser, Sebastian Braun, et al.
Pageof 7